TAKREEM’s Laureate for the Scientific and Technological Achievement for the year 2015 and president of the American University of Beirut, was honored for his service as editor-in-chief of Cancer,  a journal of the American Cancer Society, in a reception June 3 at the 2022 ASCO annual meeting. Fadlo R. Khuri, MD, became the 16th President of the American University of Beirut on September 1, 2015. Before joining AUB, Khuri was a Professor and the Roberto C. Goizueta Chair in the Department of Hematology & Medical Oncology, as well as Executive Associate Dean for Research at the Emory School of Medicine, where he was also Deputy Director of the Winship Cancer Institute. Khuri is an accomplished molecular oncologist who has conducted transformative research on oncolytic viral therapy, induction chemotherapy, and targeted therapy of tobacco-related cancers. He has developed molecular-targeted therapeutic approaches for lung and head and neck tumors that combine signal transduction inhibitors with chemotherapy, and he has led major chemoprevention efforts in lung and head and neck cancer. Cancer, is a peer-reviewed journal of the American Cancer Society that provides clinicians and researchers with the latest information they need to give patients the best-quality cancer care possible. Each issue brings the laboratory to the patient's bedside by providing readers with the latest clinical research findings and information on such critical issues as cancer prevention, early detection, diagnosis, cure, rehabilitation, and comprehensive patient care. Cancer also publishes supplements on topics of interest to oncology professionals.

For the full article:

https://cancerletter.com/in-brief/20220610_9a/